| Literature DB >> 24389282 |
Chand Wattal1, Reena Raveendran2, Neeraj Goel2, Jaswinder Kaur Oberoi2, Brijendra Kumar Rao3.
Abstract
OBJECTIVE: To analyse the prevalent microorganisms and their antimicrobial resistance among intensive care unit patients in a tertiary care centre in New Delhi.Entities:
Keywords: Antibiotic consumption; Drug resistant Candida species; Infection in ICU; Multi-drug resistance
Mesh:
Substances:
Year: 2014 PMID: 24389282 PMCID: PMC9427522 DOI: 10.1016/j.bjid.2013.07.010
Source DB: PubMed Journal: Braz J Infect Dis ISSN: 1413-8670 Impact factor: 3.257
Fig. 1Distribution of the various microorganisms from blood culture from ICU patients.
Percentage resistance of antimicrobial agents in the Gram negative bacilli.
| Percentage resistance | ||||
|---|---|---|---|---|
| Ampicillin | 96 | NT | 99 | NT |
| Ceftriaxone | 91 | 96 | 99 | NT |
| Ceftazidime | NT | NT | NT | 58 |
| Cefepime | 90 | 95 | 94 | 60 |
| Gentamicin | 64 | 88 | 86 | 73 |
| Amikacin | 20 | 66 | 78 | 68 |
| Ciprofloxacin | 93 | 91 | 89 | 71 |
| Piperacillin + tazobactam | 49 | 85 | 90 | 45 |
| Cefoperazone + sulbactum | 35 | 82 | 79 | 64 |
| Ertapenem | 13 | 70 | NT | NT |
| Imipenem/meropenem | 12 | 77 | 83 | 67 |
| Tigecycline | 0 | 28 | 47 | NT |
| Colistin | 0 | 0 | 0.5 | 0 |
ICU, Intensive care unit; NT, not tested.
Percentage resistance of Gram positive bacteria to antimicrobial agents.
| Antimicrobial agent | Percentage resistance | |||
|---|---|---|---|---|
| CoNS | ||||
| Penicillin | 100 | 99.5 | NT | 16 |
| Ampicillin | NT | NT | 77 | NT |
| Oxacillin | 47 | 94 | NT | NT |
| Ceftriaxone | NT | NT | NT | 0 |
| Clindamycin | 49 | 80 | NT | NT |
| Levofloxacin | NT | NT | NT | 0 |
| Gentamicin | 56 | 72 | NT | NT |
| Gentamicin120 | NT | NT | 84 | NT |
| Vancomycin | 0 | 0 | 23 | 0 |
| Linezolid | 0 | NT | 0 | NT |
| Tigecycline | 0 | NT | 0 | NT |
| Daptomycin | 0 | NT | 0 | NT |
ICU, intensive care unit; CoNS, coagulase negative staphylococcus; NT, not tested.
Mechanism of carbapenem resistance among Enterobacteriaceae (December 2010 to April 2011).
| MHT positive | MHT positive and MBL positive (NDM-1) | MHT positive and MBL negative (KPC) | |
|---|---|---|---|
| 1 (4.3) | 0 (0) | 1 (14.3) | |
| 17 (63) | 14 (51.9) | 3 (11.1) |
MHT, modified Hodge test; MBL, metallo-β-lactamase. Figures in parenthesis denotes percentage.
Antimicrobial use during 2008–2011.
| Antimicrobial class | DDD/100 bed days |
|---|---|
| Penicillins | 3.62 |
| Total cephalosporins | 25.92 |
| Total BL–BLI combinations | 27.62 |
| Quinolones | 10.45 |
| Aminoglycosides | 8.60 |
| Clindamycin | 8.13 |
| Carbapenem | 17.38 |
| Glycopeptides | 10.11 |
| Linezolid | 1.72 |
| Colistin | 6.23 |
| Tigecycline | 2.74 |
| Total | 122.52 |
DDD, defined daily doses; BL + BLI = β-lactam + β-lactam inhibit.
Percentage resistance of common candida isolates to antifungals.
| Most common pathogens ( | Antifungal (percentage resistance) |
|---|---|
| Amphotericin B (0), Caspofungin (0), Voriconazole (1.2), Fluconazole (3.6), Flucytosine (6.5) | |
| Flucytosine (21.3), Caspofungin (4.9), Voriconazole (20.7), Fluconazole (96.7), Amphotericin B (98.1) | |
| Amphotericin B (0), Flucytosine (1.4), Caspofungin (0), Voriconazole (17), Fluconazole (37.4) | |
| Amphotericin B (0), Caspofungin (0), Voriconazole (0), Fluconazole (0.8), Flucytosine (2.5) | |
| Amphotericin B (0), Flucytosine (0), Caspofungin (0), Voriconazole (13.6), Fluconazole (25.8) |